Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...
Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...
The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...
Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...
Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...
lupus nephritis (LN), characterized by immune system induced inflammation of the kidneys. Within 10 years, up to 20% of LN patients progress to end-stage renal disease, a potentially fatal ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva ...
Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...
The following is a summary of “Distinct genetic risk loci between biopsy-proven renal and non-renal lupus: a 10-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback